Zacks Research Forecasts Higher Earnings for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Equities research analysts at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for Globus Medical in a note issued to investors on Tuesday, March 31st. Zacks Research analyst Team now anticipates that the medical device company will post earnings of $0.89 per share for the quarter, up from their previous forecast of $0.88. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s Q3 2026 earnings at $1.14 EPS, FY2026 earnings at $4.42 EPS, Q1 2027 earnings at $1.08 EPS, Q2 2027 earnings at $1.15 EPS, Q3 2027 earnings at $1.22 EPS, FY2027 earnings at $4.67 EPS and FY2028 earnings at $5.19 EPS.

A number of other analysts have also issued reports on GMED. Royal Bank Of Canada boosted their target price on shares of Globus Medical from $92.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Canaccord Genuity Group increased their price target on shares of Globus Medical from $105.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, January 9th. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research report on Tuesday, December 30th. Wells Fargo & Company raised Globus Medical to a “strong-buy” rating in a report on Wednesday, March 18th. Finally, Truist Financial set a $115.00 price objective on Globus Medical in a report on Wednesday, February 25th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Globus Medical currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.36.

Globus Medical Stock Down 0.0%

Shares of GMED opened at $87.72 on Wednesday. Globus Medical has a 52-week low of $51.79 and a 52-week high of $101.40. The business has a fifty day moving average of $88.88 and a 200 day moving average of $80.81. The company has a market cap of $11.86 billion, a PE ratio of 22.26, a P/E/G ratio of 2.05 and a beta of 1.09.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.22. The company had revenue of $826.42 million during the quarter, compared to the consensus estimate of $803.29 million. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The firm’s revenue was up 25.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.84 EPS.

Insider Activity at Globus Medical

In other news, Director Leslie V. Norwalk sold 2,000 shares of the company’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $202,200.00. Following the completion of the transaction, the director directly owned 10,419 shares of the company’s stock, valued at approximately $1,053,360.90. This represents a 16.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Kyle Kline sold 3,594 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total transaction of $363,353.40. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 35,594 shares of company stock valued at $3,332,253 over the last quarter. 18.51% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Invesco Ltd. lifted its position in Globus Medical by 1,235.2% during the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock worth $339,322,000 after buying an additional 3,595,339 shares during the period. Bank of Montreal Can increased its stake in shares of Globus Medical by 15,317.1% during the 4th quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock valued at $294,519,000 after acquiring an additional 3,351,380 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Globus Medical by 1,303.9% in the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock worth $117,700,000 after acquiring an additional 1,908,795 shares during the last quarter. Boston Trust Walden Corp purchased a new stake in Globus Medical in the third quarter valued at approximately $67,891,000. Finally, Norges Bank acquired a new position in Globus Medical during the second quarter worth approximately $68,038,000. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical News Roundup

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks raised its Q1 2028 EPS forecast to $1.20 (from $1.19) and reiterated a “Strong‑Buy” rating — a direct, recent upgrade to near‑term earnings expectations that can boost investor confidence. MarketBeat GMED
• Positive Sentiment: Multiple small upward revisions across quarters (Q1–Q3 2026, Q1–Q3 2027) and fiscal years (FY2026, FY2027, FY2028) — including FY2026 to $4.42, FY2027 to $4.67 and FY2028 to $5.19 — suggest Zacks is modeling modestly stronger revenue/profit trends over the next several years. This broad-based upgrade pattern is a constructive signal for growth expectations. MarketBeat GMED
• Neutral Sentiment: Valuation and technical backdrop: GMED trades with a market cap ~ $11.9B and a P/E ~22x; the stock sits near its 50‑day moving average (~$88.9) above the 200‑day (~$80.8). These factors moderate how quickly upgrades translate into price moves — investors will watch upcoming results and guidance for confirmation. MarketBeat GMED

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.